The needle and the damage done

Annals of the Rheumatic Diseases

Volumn 64, Issue 6, 2005, Pages 798-800

  Franz, J K ^a   Burmester, G R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHLOROQUINE; CORTICOSTEROID; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; UNCLASSIFIED DRUG;

ARTHROSCOPY; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; JOINT BIOPSY; MACROPHAGE; NEEDLE BIOPSY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYNOVIUM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOPSY, NEEDLE; EVIDENCE-BASED MEDICINE; HUMANS; MACROPHAGES; SYNOVIAL MEMBRANE; TREATMENT OUTCOME;

EID: 19544372614     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.039248     Document Type: Short Survey

References (32)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, Hart BA, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998;41:1481-8.
3. Burmester GR, Shjhlmüller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum 1997;40:5-18.
4. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res 2000;2:189-202.
5. Stuhlmüller B, Ungethüm U, Scholze S, Martinez L, Backhaus M, Kraetsch H-G, et al. Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis. Arthritis Rheum 2000;43:775-90.
6. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39:115-24.
7. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50:3783-91.
8. Yanni G, Nabil M, Faharat MR, Poston RN, Panayi GS. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis 1994;53:315-22.
9. Pettit AR, Weedon H, Ahern M, Zehntner S, Frazer IH, Slavotinek J, et al. Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis. Rheumatology (Oxford) 2001;40:1243-55.
10. Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P, Breedveld FC, Miltenburg AM. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998;37:502-8.
11. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJM, Kraan MC, Beaten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:834-8.
12. Amano Y, Lee SW, Allison AC. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation of decreased mRNA stability. Mol Pharmacol 1993;43:176-82.
13. Loetscher P, Dewald B, Baggiolini, Seitz M. Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs. Cytokine 1994;6:162-70.
14. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793-802.
15. Verhoef CM, Van Roon JA, Vianen ME, Lafeber FP, Bijlsma JW. The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. Ann Rheum Dis 1999;58:49-54.
16. Smeets TJ, Krann MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003;48:2155-62.
17. Bondeson J. The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmocol 1997;29:127-50.
18. Nakamura H, Igarashi H. Localization of gold in synovial membrane of rheumatoid arthritis treated with sodium aurothiomalate. Studies by electron microscope and electron probe x-ray microanalysis. Ann Rheum Dis 1977;36:209-15.
19. Hayman AR, Cox TM. Tartrate-resistant acid phosphatase: a potential target for therapeutic gold. Cell Biochem Funct 2004;22:275-80.
20. Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, et al. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 1995;34:602-9.
21. Cronstein BN. Therapeutic cocktails for rheumatoid arthritis: the mixmaster's guide. Arthritis Rheum 2004;50:2041-3.
22. Kobayashi Y, Ueyama S, Arai Y, Yoshida Y, Kaneda T, Sato T, et al. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage. J Bone Miner Metab 2004;22:318-28.
23. Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells. Arthritis Rheum 2004;50:794-804.
24. Cutolo M, Sulli A, Ghiorzo P, Pizzorni C, Craviotto C, Villaggio B. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:297-302.
25. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43:1820-30.
26. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, et al. Evidence that antitumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005;52:61-72.
27. Cunnane G, Madigan A, Murphy E, Fitzgerald O, Bresnihan B. The effect of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) 2001;40:62-9.
28. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dix 2003;62:715-21.
29. Burmester GR, Locher P, Koch B, Winchester RJ, Dimitriu-Bona A, Kalden JR, et al. The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens. Rheumatol Int 1983;3:173-81.
30. Rhodes LA, Tan AL, Tanner SF, Radjenovic A, Hensor EM, Reece R, et al. Regional variation and differential response to therapy for knee synovitis adjacent to the cartilage-ponnus junction and suprapatellar pouch in inflammatory arthritis: implications for pathogenesis and treatment. Arthritis Rheum 2004;50:2428-32.
31. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology. Role of synovial fioroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000;2:361-7.
32. Singh JA, Pando JA, Tomaszewski J, Schumacher HR. Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug and corticosteroid-naive patients. J Rheumatol 2004;31:1281-5.